Recognizing and managing comorbidities in psoriatic arthritis

Current Opinion in Rheumatology

Volumn 27, Issue 2, 2015, Pages 118-126

  Ogdie, Alexis ^a   Schwartzman, Sergio ^b   Husni, M Elaine ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

comorbidity; management; psoriatic arthritis; screening

Indexed keywords

ANXIETY DISORDER; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMORBIDITY; CROHN DISEASE; DEPRESSION; DIABETES MELLITUS; EYE DISEASE; FATTY LIVER; HUMAN; INFLAMMATORY BOWEL DISEASE; KIDNEY DISEASE; LIVER DISEASE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; OBESITY; OSTEOPOROSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; REVIEW; RISK ASSESSMENT; SCREENING; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EYE DISEASES; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; LIVER DISEASES; MENTAL DISORDERS; NEOPLASMS;

ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; EYE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; LIVER DISEASES; MENTAL DISORDERS; NEOPLASMS; OBESITY; OSTEOPOROSIS;

EID: 84922399380     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000152     Document Type: Review

References (119)

1. Ogdie A, Schwartzman S, Eder L, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 2014; 41:2315-2322.
2. Husted J, Thavaneswaran A, Chandran V, Gladman D. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol 2013; 40:1349-1356.
3. Sanchez-Carazo J, López-Estebaranz J, Guisado C. Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). J Dermatol 2014; 41:673-678.
4. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27 (Suppl 3):12-29.
5. Jamnitski A, Symmons D, Peters MJL, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72:211-216.
6. Beinsberger J, Heemskerk J, Cosemans J. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum 2014; 44:345-352.
7. Khraishi M, Aslanov R, Rampakakis E, et al. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol 2014; 33:1495-1500.
8. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011; 63:1729-1735.
9. Eder L, Thavaneswaran A, Chandran V, et al. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patientswith psoriatic arthritis. Ann Rheum Dis 2014. [Epub ahead of print]
10. Labitigan M, Bahče-Altuntas A, Kremer JR, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66:600-607.
11. Bostoen J, Van Praet L, Brochez L, et al. A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol 2014; 28:507-511.
12. Puig L, Strohal R, Husni ME, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat 2013. [Epub ahead of print]
13. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014; 41:1357-1365.
14. Lin YC, Dalal D, Churton S, et al. Relationship of metabolic syndrome and CIMT measures: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 2014; 66:97-103.
15. USPSTF. USPSTF Draft recommendations for screening for abnormal glucose and type 2 diabetes mellitus. http://www.uspreventiveservicestaskforce. org/Page/Document/EvidenceReportDraft/screening-for-abnormalglucose- and-type-2-diabetes-mellitus. [Accessed 9 October 2014]
16. WHO. FRAX: fracture risk assessment tool. http://www.shef.ac.uk/FRAX/tool.jsp?locationValue=9. [Accessed 9 October 2014]
17. Eder L, Chandran V, Gladman D. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 2014; 73:1990-1996.
18. Rosales Alexander J, Cantero-Hinojosa J, Salvatierra J, et al. Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Joint Bone Spine 2014; 81:164-168.
19. Torres T, Sales R, Vasconcelos C, et al. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 2013; 40:923-926.
20. Favarato M, Mease P, Goncalves C, et al. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol 2014; 32:182-187.
21. Puato M, Ramonda R, Doria A, et al. Impact of hypertension on vascular remodeling in patients with psoriatic arthritis. J Hum Hypertens 2014; 28:105-110.
22. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889-2934.
23. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Cholesterol Guideline Panel. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014; 160:339-343.
24. Tam L, Kitas G, Gonzalez-Gay M. Can suppression of inflammation by anti- TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 2014; 53:1108-1119.
25. Armstrong A, Brezinski E, Follansbee M, Armstrong E. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 2014; 20:500-512.
26. MontaudiéH, Albert-Sabonnadiere C, Acquacalda E, et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2014; 28:1186-1191.
27. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL- 12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological antitumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73:990-999.
28. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-789.
29. McKeage K. Ustekinumab: a review of its use in psoriatic arthritis. Drugs 2014; 74:1029-1039.
30. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013; 15 (Suppl 13):S2.
31. Day RO. Nonsteroidal anti-inflammatory drugs. Br Med J 2013; 346:f3195.
32. Lindhardsen J, Gislason GH, Jacobsen S, et al. Nonsteroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2013. [Epub ahead of print]
33. Ng MKC, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. Heart 2004; 90:829-830.
34. Amer M, Bead VR, Bathon J, et al. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 2010; 18:204-212.
35. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of antitumor necrosis factor therapy. Am J Med 2004; 116:305-311.
36. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51:v38-v47.
37. Jain A, Singh JA. Harms of tumor necrosis factor inhibitors in rheumatic diseases: a focused systematic review of the literature. Immunotherapy 2013; 5:265-299.
38. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012; 51:552-556.
39. Love T, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012; 71:1273-1277.
40. Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010; 146:721-726.
41. Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcomes and management. Rheumatology (Oxford) 2013; 52:62-67.
42. Versini M, Jeandel P, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014; 13:981-1000.
43. Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2014. [Epub ahead of print]
44. Di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013; 65:141-147.
45. Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis 2014; 73:1157-1162.
46. Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res (Hoboken) 2014; 66:1159-1166.
47. MontaudiéH, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25 (Suppl 2):12-18.
48. Gisondi P, Cotena C, Tessari G, Girolomoni G. Antitumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22:341-344.
49. Prignano F, Ricceri F, Pescitelli L, et al. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 2009; 25:2311-2316.
50. Saraceno R, Schipani C, Mazzotta A, et al. Effect of antitumor necrosis factoralpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57:290-295.
51. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73:1020-1026.
52. Dubreuil M, Hee Rho Y, Man D, et al. The independent impact of psoriatic arthritis and rheumatoid arthritis on diabetes incidence: a UK populationbased cohort study. Rheumatology (Oxford) 2014; 53:346-352.
53. Coto-Segura P, Eiris-Salvado N, Gonzalez-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 2013; 169:783-793.
54. Dreiher J, Freud T, Cohen A. Psoriatic arthritis and diabetes: a populationbased cross-sectional study. Dermatol Res Pract 2013; 2013:580404.
55. Solomon D, Love T, Canning C, et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010; 69:2114-2117.
56. Solomon D, Massarotti E, Garg R, et al. Association between diseasemodifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. J Am Med Assoc 2011; 305:2525-2531.
57. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46:1111-1118.
58. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. http://www.who.int/diabetes/publications/diagnosis-diabetes2006/en/. [Accessed 16 April 2014]
59. US Preventive Services Task Force. Screening for type 2 diabetes in adults. http://www.uspreventiveservicestaskforce.org/uspstf08/type2/type2- summ.htm. [Accessed 3 April 2014]
60. Li W, Han J, Chan A, Qureshi A. Psoriasis, psoriatic arthritis and increased risk of incident Crohns disease in US women. Ann Rheum Dis 2013; 72:1200-1205.
61. Crohns and Colitis Foundation. Maintenance therapy. http://www.ccfa.org/resources/maintenance-therapy.html. [Accessed 16 April 2014]
62. Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res 2014; 163:533-556.
63. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohns disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-1094.
64. Paiva E, Macaluso D, Edwards A, Rosenbaum J. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 2000; 59:67-70.
65. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008; 67:955-959.
66. Queiro R, Torre J, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002; 31:264-270.
67. Lima F, Abalem M, Ruiz D, et al. Prevalence of eye disease in Brazilian patients with psoriatic arthritis. Clinics (Sao Paulo) 2012; 67:249-253.
68. Altan-Yaycioglu R, Akova Y, Kart H, et al. Posterior scleritis in psoriatic arthritis. Retina 2003; 23:717-719.
69. Lambert J, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis 1976; 35:354-356.
70. Servat J, Mears K, Black E, Huang J. Biological agents for the treatment of uveitis. Expert Opin Biol Ther 2012; 12:311-328.
71. Martel J, Esterberg E, Nagpal A, Acharya N. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 2012; 20:18-26.
72. Kruh J, Foster C. The philosophy of treatment of uveitis: past, present and future. Dev Ophthalmol 2012; 51:1-6.
73. Smith J, Thompson D, Whitcup S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53:18-23.
74. Lim L, Fraunfelder F, Rosenbaum J. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56:3248-3252.
75. Del Puente A, Esposito A, Parisi A, et al. Osteoporosis and psoriatic arthritis. J Rheumatol Suppl 2012; 89:36-38.
76. Busquets N, Vaquero C, Moreno J, et al. Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Reumatol Clin 2014; 10:89-93.
77. Riesco M, Manzano F, Font P, et al. Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. Clin Rheumatol 2013; 32:1799-1804.
78. Attia E, Khafagy A, Abdel-Raheem S, et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol 2011; 50:30-35.
79. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postemenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther 2011; 13:R16.
80. Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: a review. J Womens Health 2014; 23:563-572.
81. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:1515-1526.
82. Kawai V, Grijalva C, Arbogast P, et al. Initiation of tumor necrosis factor a antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) 2013; 65:1085-1094.
83. Rohekar S, Tom B, Hassa A, et al. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008; 58:82-87.
84. Ogdie A, Maliha S, Love T, et al. Cause-specific mortality in patients with psoriatic arthritis. Ann Rheum Dis 2013; 72 (Suppl 3):519.
85. Hellgren K, Smedby K, Backlin E, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 2014; 66:1282-1290.
86. Gross RL, Schwartzman-Morris JS, Krathen M. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 2014; 66:1472-1481.
87. Stone JH. Tumor necrosis factor-alpha inhibitors: risk of malignancy. JT In: UpToDate, Furst DE (Ed), UpToDate, Waltham, MA. (Accessed on January 6, 2015).
88. Dommasch E, Abuabara K, Shin D, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64:1035-1050.
89. Mercer LK, Low ASL, Galloway JB, et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis 2013; 72:143-144.
90. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625-639.
91. Gisondi P, Targher G, Zoppini G, Girolomoni G. Nonalcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51:758-764.
92. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of nonalcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51:778-786.
93. Di MinnoM, Iervolino S, Peluso R, et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-a blockers. J Rheumatol 2012; 39:1042-1046.
94. Curtis J, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43-47.
95. Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009; 48:1107-1110.
96. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006; 26:55-62.
97. Langman G, Hall P, Todd G. Role of nonalcoholic steatohepatitis in methotrexate- induced liver injury. J Gastroenterol Hepatol 2001; 16:1395-1401.
98. Bath RK, Brar NK, Forouhar FA,WuGY. A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014; 15:517-524.
99. OConnor N, Dargan PI, Jones AL. Hepatocellular damage from nonsteroidal anti-inflammatory drugs. Q J Med 2003; 96:787-791.
100. Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:1612-1617.
101. Kavanaugh A, Greenberg J, Lee S, et al. Incidence of elevated liver enzymes (LFTS) in psoriatic arthritis (PS) patients: effect of TNF-inhibitors (TNF-I). Ann Rheum Dis 2010; 69 (Suppl 3):579.
102. Seitz M, Reichenbach S, Möller B, et al. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010; 69:1148-1150.
103. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-784.
104. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-a inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013; 19:7867-7873.
105. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing antitumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16:527-531.
106. Haroon M, Adeeb F, Devlin J, et al. A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with antirheumatic therapies, inflammatory markers or duration of arthritis. Int J of Rheum 2011; 14:255-260.
107. Levy AR, Szabo SM, Rao SR, et al. Estimating the occurrence of renal complications among persons with ankylosing spondylitis. Arthritis Care Res (Hoboken) 2014; 66:440-445.
108. Bressolle F, Bologna C, Kinowski JM, et al. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis. Ann Rheum Dis 1998; 57:110-113.
109. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systemic review of treatment modalities, risk of kidney toxicity and evidence for use in nonplaque psoriasis. J Eur Acad Dermatol Venereol 2011; 25 (Suppl 2):19-27.
110. Fine M. Quantifying the impact of NSAID-associated adverse events. Am J Manag Care 2013; 19 (14 Suppl):s267-s272.
111. Al-Hasani H, Roussou E. Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 2011; 31:1545-1547.
112. Bergner R, Peters L, Schmitt V, Loffler C. Leflunomide in dialysis patients with rheumatoid arthritis: a pharmacokinetic study. Clin Rheumatol 2013; 32:267-270.
113. Senel S, Kisacik B, Ugan Y, et al. The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 2011; 30:1369-1372.
114. Don BR, Spin G, Nestorov I, et al. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 2005; 57:1407-1413.
115. Bandinelli F, Prignano F, Bonciani D, et al. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clin Exp Rheumatol 2013; 31:318-319.
116. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014; 41:887-896.
117. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical healthrelated quality of life. Arthritis Care Res (Hoboken) 2012; 64:1593-1601.
118. Husted JA, Tom BD, Farewell VT, Gladmann DD. Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 2012; 64:758-765.
119. OTEZLA1 (apremilast) prescribing information. http://www.otezlapro.com/wp-content/uploads/2014/09/otezla-prescribing-information.pdf. [Accessed 7 October 2014]